Immunic, Inc. (IMUX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XMUN Summary
Immunic adds new Chief People Officer ahead of Phase 3 readout
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has appointed Jaa Roberson as its first Chief People Officer, adding a senior human resources leader as the biotechnology company prepares for a pivotal multiple sclerosis trial readout expected by the end of 2026. Roberson will report to CEO Erik Lundgren and join the executive leadership team.
Immunic to present four vidofludimus calcium abstracts at MSToronto2026
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said four abstracts on its lead MS drug candidate, vidofludimus calcium, have been accepted for presentation at the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto from October 21 to 23. The oral therapy is a Nurr1 activator under development for neurologic diseases.
Immunic to host virtual relapsing MS R&D Day on September 9
Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced that it will host a virtual research and development day focused on relapsing multiple sclerosis on September 9, as the biotechnology company prepares for topline results from its Phase 3 ENSURE trials expected by the end of 2026. The event will feature Immunic management, including CEO Erik Lundgren, chief medical officer Michael Panzara, chief scientific officer Hella Kohlhof and president and chief operating officer Jason Tardio.
Immunic, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ABB Alexander Bjornager Bonde Danske Bank A/S | 2 | $31 | $14.36 | -$16.64 | -53.68% |
| MS Matthew Sutula ALPS ADVISORS Inc. | 13,824 | $212,474.88 | $100,638.72 | -$111,836.16 | -52.64% |
| MM Masih Mohebbi Laurion Capital Management LP | 610,326 | $9.38M | $4.43M | -$4.95M | -52.77% |
| DRO Donal Reamonn O'Sullivan Brevan Howard Capital Management LP | 4,584.3 | $50,885.73 | $32,915.27 | -$17,970.46 | -35.32% |
| KE Kathleen Engler Baader Bank Aktiengesellschaft | 1,128.1 | $12,521.91 | $8,206.93 | -$4,314.98 | -34.46% |
Immunic, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| YS Yanni Souroutzidis Cantor Fitzgerald | 13,103.92 | $96,313.82 | $93,037.84 | -$3,275.98 | -3.4% |
Immunic, Inc. (IMUX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Immunic, Inc. ever had a stock split?
Immunic, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Erik Lundgren CEO | NASDAQ (NGS) Exchange | 4525EP200 CUSIP |
| US Country | 100 Employees | 15 Apr 2019 Last Dividend | 27 Apr 2026 Last Split | 17 Apr 2014 IPO Date |
Overview
Immunic, Inc. is a biotechnology company with a core focus on the development of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Established in 2016 and with operations in both the United States and Germany, Immunic, Inc. dedicates itself to advancing a pipeline of novel treatments that promise a brighter future for patients suffering from these debilitating conditions. By targeting the underlying causes of such diseases, Immunic strives to deliver effective and innovative medical solutions that can improve the quality of life for those affected.
Products and Services
- IMU-838 - This leading drug candidate is currently in Phase 3 clinical trial stages, focusing on the treatment of multiple sclerosis, including both relapsing and progressive types, as well as moderate-to-severe ulcerative colitis. IMU-838 represents Immunic, Inc.'s commitment to addressing auto-immune challenges through selective oral immunology therapies, targeting a critical need in the management of auto-immune and inflammatory diseases.
- IMU-856 - Poised to enter Phase 2 clinical trials, IMU-856 is being developed as a solution for the restoration of intestinal barrier function in patients suffering from a variety of gastrointestinal diseases. These include celiac disease, inflammatory bowel disease, short bowel syndrome, and irritable bowel syndrome with diarrhea, among others. This product focuses on restoring the natural defense mechanisms of the gastrointestinal tract, which is a novel approach to treating these conditions.
- IMU-381 - Still in the preclinical trial phase, IMU-381 is designed to target gastrointestinal diseases, with a focus on a new method of treatment. Although details about its specific action are less advanced than those of IMU-838 and IMU-856, IMU-381 represents Immunic, Inc.'s ongoing efforts to expand its portfolio and tackle a broader range of inflammatory and autoimmune diseases through innovative therapeutic approaches.
Contact Information
